Clinical Trials Insight: 700029357

Trial Profile

Clinical Trials Insight: 700029357

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2009

At a glance

  • Drugs Caplacizumab (Primary)
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Sponsors Ablynx
  • Most Recent Events

    • 22 Dec 2009 Results from the open label extension were reported in a Ablynx media release.
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed, according to a Ablynx media release.
    • 01 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported in an Ablynx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top